Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Other Accumulated Expenses (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Other Accumulated Expenses for 13 consecutive years, with $96.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses rose 152.83% year-over-year to $96.9 million, compared with a TTM value of $96.9 million through Sep 2025, up 152.83%, and an annual FY2024 reading of $49.3 million, up 73.26% over the prior year.
  • Other Accumulated Expenses was $96.9 million for Q3 2025 at Tandem Diabetes Care, down from $100.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $100.0 million in Q2 2025 and bottomed at $18.3 million in Q2 2021.
  • Average Other Accumulated Expenses over 5 years is $39.5 million, with a median of $30.1 million recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses fell 2.94% in 2023, then surged 202.63% in 2025.
  • Year by year, Other Accumulated Expenses stood at $23.4 million in 2021, then increased by 25.38% to $29.3 million in 2022, then decreased by 2.94% to $28.5 million in 2023, then skyrocketed by 73.26% to $49.3 million in 2024, then surged by 96.47% to $96.9 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for TNDM at $96.9 million in Q3 2025, $100.0 million in Q2 2025, and $91.8 million in Q1 2025.